핀란드 - 핀란드어 - Fimea (Suomen lääkevirasto)

teva b.v. - metformin hydrochloride, vildagliptin - tabletti, kalvopäällysteinen - 50 mg / 850 mg - metformiini ja vildagliptiini

핀란드 - 핀란드어 - Fimea (Suomen lääkevirasto)

teva b.v. - metformin hydrochloride, vildagliptin - tabletti, kalvopäällysteinen - 50 mg / 1000 mg - metformiini ja vildagliptiini

핀란드 - 핀란드어 - Fimea (Suomen lääkevirasto)

stada arzneimittel ag - metformin hydrochloride, vildagliptin - tabletti, kalvopäällysteinen - 50 mg / 1000 mg - metformiini ja vildagliptiini

핀란드 - 핀란드어 - Fimea (Suomen lääkevirasto)

stada arzneimittel ag - metformin hydrochloride, vildagliptin - tabletti, kalvopäällysteinen - 50 mg / 850 mg - metformiini ja vildagliptiini

유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

novartis europharm limited - vildagliptiini, metformiinihydrokloridia - diabetes mellitus, tyyppi 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

novartis europharm limited - vildagliptiini, metformiinihydrokloridia - diabetes mellitus, tyyppi 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 käytettävissä olevista tiedoista eri yhdistelmistä).

유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptiini, metformiinihydrokloridia - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 käytettävissä olevista tiedoista eri yhdistelmistä).

핀란드 - 핀란드어 - Fimea (Suomen lääkevirasto)

krka, d.d., novo mesto - metformin hydrochloride, vildagliptin - tabletti, kalvopäällysteinen - 50 mg / 1000 mg - metformiini ja vildagliptiini

핀란드 - 핀란드어 - Fimea (Suomen lääkevirasto)

krka, d.d., novo mesto - metformin hydrochloride, vildagliptin - tabletti, kalvopäällysteinen - 50 mg / 850 mg - metformiini ja vildagliptiini